i want to come back to the fact that the teva deal will be on.hey'll get the $40 billion. >> one thing you have not talked about is pfizer what about that name? what happens there? there was a plan to break apart. do you move that up? >> if you value it like merck, it's going to be at 30. >> that's where it is. >> well -- 31. >> we have valeant news it la completed its review of its relationship with specialty pharmacy philidor. it has not found additional items that they say will require restatement and still intends to file that annual by april 29th. >> once again, i know the stock will be up. having followed these kinds of investigations, when a company declares itself clean, that means nothing. okay? nothing. it's the s.e.c. that declares you're clean. they could say we looked at it up and down. we're good. do you think the s.e.c. cares at all? oh, so you guys sat around and you talked among yourselves, you got ackman there. you got some really good guys. you blessed it? okay, we'll leave it. that's the opposite of what happens. it's the oppo

about 70 mid states or late states and what a pipeline and oh by the way they get 40 billion on the teval so they're going to have cash and be able to keep using the stock itself. there's going to be acquisitions for the company. >> you're staying at such. and over the last couple of days still continue to do something. >> that stock is soaring today on the heels of bill ackman's call with investors moments ago after posting a record quarter loss. and listening in and has the very latest. and regain most of his investment value overtime. and hedge fund manager lost about a billion dollars since activities can first took a state in the drug company last march. now otolaryngologylining three ways they will regain through improved governance and filing it's 10-k which it is expecting to do in april. a hand full of candidates are being considered for the ceo role after mike pearson stepped down recently. ackman didn't give any more additional research on the search. now it's still betting on a merger between canadian pacific and norfolk southern and it will get a vote of confidence and there

cowan had had a note out earlier saying what could allergen do with the teva pharmaceuticals, only thisch means these ones are undervalued. >> yeah. >> this name is way oversold and this is a name they looked at a year ago. >> it's a $60 billion market cap. would have to get -- >> all of a sudden they are -- obviously it would be a cash stock. >> isn't it time to take on debt with interest rates and mr mr. zerp? >> yeah. >> i would just say it would depend on what growth. it's a big rollup. >> if you folks like hang man at home the most difficult word to guess in hang man is jazz. want to play hangman. >> because of the "j" and "zs." >> jazz, just remember that. >> that's a -- genius. >> the more you know. >> steve wynn speaking at the wynn investor conference heading higher after hours, more about the quarter, his health and more of the conversation with disney's bob iger. you're watching cnbc, first in business worldwide. recommend synthetic over cedar?u "super food?" is that a real thing? it's a great school, but is it the right one for her? is this really any better than the one you

they have money coming in from their generic sale to teva, which should close in the next few months.t works in their favor is a competitor, former competitor is probably not going to be in the deal game . there are things that they might want to buy like bausch & lomb, which brent saunders used to be the ceo of. i think you will see more deals for allergan going forward then you will four pfizer. scarlet: coming up next, that, bath and beyond reports earnings after the bell and analyst brace for a slowing quarter -- up next, bed, bath, and beyond reports earnings after the bell. ♪ scarlet: this is "bloomberg markets." a look at some of the biggest business stories in the news right now. halliburton is being sued by u.s. and trust officials who said a planned takeover of their rival prevents competition and should be blocked. the attorney general addressed the proposed merger earlier today. ag lynch: if completed, it would remove competition and 20 markets and hamper america's efforts to become energy independent, a setback that would harm not only our economic well-being but also our

. >> which sounds like what you plan on doing once you get the money in from teva. >> absolutely. >> do you have a list? >> yes. i've always maintained a list. and, yes, we do. >> i have to ask you something. valeant had this terrific, trivgs determine toe logic business. they laid off dermatologists. you've got botox over here. i mean have you destroy ed dest portion of the business? >> we continue to be strong in the industry. >> have you destroyed their business? >> i think they have, right. >> once again, no interest whatsoever. say bill ackman called you right now, would you become ceo? >> i would not. i have the best ceo position in the industry. i love allergan, the industry, the future, i love our people. there's not one temptation for me to leave. and, in fact, with pfizer, i wasn't going to leave. >> is that a benefit? having bill ackman call you constantly, is that a good thing? >> i actually like him. he's a smart man. >> how many times day does he call? >> i have a lot of respect for him. >> have you spoken to lew since this news. >> i have not. >> when the company says

approval in the u.s., but either way you're looking at a company that on a core basis, just forget about tevang sales 8% organically. we are not talking 4% of that as a price. >> you might have liked the next stock a while ago, i don't know, but alcoa, it's just interesting timing today because while you can make again the arguments, the stock is up 52% in three months. i mean, when i see an alcoa, which i don't know has gained 52% ever in the history of the company, in three months it makes you do a double-take. >> i agree. alcoa -- no one is buying this stock or very few people are buying this stock ahead of the split-up. which happens in the fourth quart quarter, they want to completely eliminate the volatility we see in the stock. one of the pure businesses is the aluminum cycle, if it's working, it will have cash flow. the other one is a much more -- it should be getting credit for trading as a multi -- maybe i wouldn't buy it right at this point, let it come down a little bit, but when i look at trough multiples in the company's history. if i assume trough multiples on both sides of the